Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986327 | 0.82 | ALOX5 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL24972582 | 0.81 | ALOX5 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8224692 | 0.78 | CYP2A6 (0.42) | ALOX5 | |
| SCHEMBL17929805 | 0.78 | ALOX5 (0.30) | ALOX5 | |
| SCHEMBL9967681 | 0.78 | ALDH1A1 (0.43) | ALOX5G6PC1NPC1RAB9AALDH1A1 | |
| SCHEMBL45858 | 0.78 | — | — | |
| SCHEMBL827337 | 0.78 | ALOX5 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL18412746 | 0.76 | ALOX5 (0.38) | ALOX5MEN1KMT2ANPC1RAB9A | |
| SCHEMBL12508123 | 0.76 | ALOX5 (0.56) | ALOX5NPC1RAB9A | |
| SCHEMBL14450192 | 0.75 | SLC6A4 (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381159-A1 | SMALL MOLECULE INHIBITORS OF CORONAVIRUS ATTACHMENT AND ENTRY, METHODS AND USES THEREOF | UNIVERSITY OF MIAMI | 2023-11-30 | — | — | US | disclosed |
| US-11820759-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820759-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230049402-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2023-02-16 | — | — | US | disclosed |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | CAYMAN CHEMICAL COMPANY, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220127252-A9 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL CO INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220009912-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20210380574-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2021-12-09 | — | — | US | disclosed |
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | UNITY BIOTECHNOLOGY, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-10988464-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2012142245-A2 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE GOVERNMENT OF THE UNITED OF AMERIA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20120208889-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUE, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-08-02 | — | — | US | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| EP-2010289-B1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-30 | — | — | EP | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100093721-A1 | PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-7205328-B2 | Aids viricide | IRM LLC (BM) | 2007-04-17 | — | — | US | disclosed |
| US-7205328-B2 | Aids viricide | IRM LLC (BM) | 2007-04-17 | — | — | US | disclosed |
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988464-B2 | Modulators of chemokine receptors | CCR5, CXCR3, CCR2 | CHRM2 2240/4885CHRM4 1643/4885CHRM5 2090/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CHRM2 4855/4885CHRM4 4823/4885CHRM5 4774/4885 |
| US-11820759-B2 | Modulators of chemokine receptors | CCR5, CXCR3, CCR2 | CHRM2 2240/4885CHRM4 1643/4885CHRM5 2090/4885 |
| US-20230381159-A1 | SMALL MOLECULE INHIBITORS OF CORONAVIRUS ATTACHMENT AND ENTRY, METHODS AND USES THEREOF | ACE2, ACE, SARS1 | CHRM2 3836/4885CHRM4 2724/4885CHRM5 1961/4885 |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | DHPS, FDPS, DPYD | CHRM2 4745/4885CHRM4 4755/4885CHRM5 4846/4885 |
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | CHRM2 4853/4885CHRM4 4846/4885CHRM5 4791/4885 |
| US-20120208889-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | HDAC1, HDAC5, HDAC6 | CHRM2 4817/4885CHRM4 4848/4885CHRM5 4779/4885 |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | PTGER4, PTGER1, PTGIR | CHRM2 49/4885CHRM4 31/4885CHRM5 107/4885 |
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | ACAT1, ARSA, GLA | CHRM2 4568/4885CHRM4 4739/4885CHRM5 4792/4885 |
| US-20220009912-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CCR5, CXCR3, CCR2 | CHRM2 2240/4885CHRM4 1643/4885CHRM5 2090/4885 |
| US-20230049402-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | MYB, MLX, EP300 | CHRM2 160/4885CHRM4 311/4885CHRM5 204/4885 |
| US-20100093721-A1 | PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | CHRM2 83/4885CHRM4 310/4885CHRM5 121/4885 |
| US-20220127252-A9 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | PTGER4, PTGER1, PTGIR | CHRM2 49/4885CHRM4 31/4885CHRM5 107/4885 |
| US-20210380574-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | RSU1, KRAS, NRAS | CHRM2 1190/4885CHRM4 3560/4885CHRM5 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.